A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer and Expansion Phase in Subjects with Advanced EGFR mutated Non-Small Cell Lung Cancer who are resistant to EGFR tyrosine kinase inhibitors - BRICE

FONDAZIONE RICERCA TRASLAZIONALE (FORT)0 个研究点目标入组 48 人开始时间: 2021年6月8日最近更新: 2024年3月12日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 48

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Inclusion criteria Part 1 only
•1)Histologically confirmed advanced EGFR mutated or ALK positive or ROS1 positive tumors resistant to available specific inhibitors.
•Part 2 only
•1)Acquired resistance to EGFR TKIs defined as progression of disease according to RECIST 1.1 during osimertinib treatment and presence of on-target mechanism of resistance, i.e. secondary or tertiary resistance mutations of EGFR, on circulating tumor DNA or tumor tissue obtained before treatment start and after any intervening systemic treatment
•Parts 1 and 2
•1)Age 18 years or older
•2)Willingness to provide written informed consent.
•3)Life expectancy >12 weeks.
•4)ECOG performance status of 0 to 1.
•5)Presence of measurable disease per RECIST v1.1 as determined by the site study team. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. The lesion selected for pre- and/or post-treatment biopsy cannot be the only measurable lesion.
•6)Female patients should be using adequate contraceptive measures, should not be breastfeeding until 120 days after the last dose, and must have a negative pregnancy test (serum or urine) prior to first dose of study drug (within 72 hours); or female patients must have an evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
•a.Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.
•b.Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution.
•c.Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.
•Female patients must meet 1 of the following:
•Postmenopausal for at least 1 year before the screening visit, or
•Surgically sterile, or
•If they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing of the informed consent form through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
•Brigatinib may decrease effectiveness of hormonal contraceptives, therefore, women are recommended to use non-hormonal methods of contraception. Highly effective non-hormonal birth control for women of child bearing potential with male partners includes:
•Sexual abstinence (no sexual intercourse)
•Intrauterine device (IUD) or intrauterine system (IUS)
•Bilateral tubal ligation (both tubes tied)
•Vasectomized partner
•7)Male patients should be willing to use barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from heterosexual intercourse
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 32
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 16

排除标准

•1)Off target mechanisms of actions, such as mutations or amplification of other genes, changes of histology, etc.
•2)Lab assessments as follows:
•a.Absolute neutrophil count <1.5 × 109/L.
•b.Platelet count <100 × 109/L.
•c.Hemoglobin <9 g/dL (transfusion is acceptable to meet this criterion).
•d.Serum creatinine =1.5 × institutional upper limit of normality (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine or CrCl) <50 mL/min for subjects with creatinine levels >1.5 × institutional ULN).
•e.Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase =2.5 × ULN. Subjects with 1) bone metastases and 2) no hepatic parenchymal metastases on screening radiographic examinations may enroll if the alkaline phosphatase is <5 × ULN. Subjects with hepatic parenchymal metastases on screening radiographic examinations may enroll if the aspartate aminotransferase and alanine aminotransferase are >2.5 × ULN only with medical monitor approval.
•f.Total bilirubin =1.5 × ULN.
•g.International normalized ratio or prothrombin time (PT) >1.5 × ULN.
•h.Activated partial thromboplastin time (aPTT) >1.5 × ULN.
•3)Anticancer medications or investigational drugs within the following ranges:
•a.<14 days for chemotherapy, targeted small-molecule therapy or radiation therapy;
•b.<28 days or 5-half-lives (whichever is longer) before first dose of investigational combination therapy.
•4)Subjects with previous grade 3 or 4 adverse event to anti-EGFR treatment, even if the toxicity is related only to laboratory anomalies and the subjects are asymptomatic
•5)History or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis
•6)Subjects who have not recovered adequately from toxicity and/or complications from surgical intervention prior to starting therapy.
•8)Evidence or history of interstitial lung disease or active non-infectious pneumonitis.
•9)Concomitant medication with strong inhibitors or inducers of CYP2C8 and CYP3A4.
•10)Known active CNS metastases. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks before the first dose of study treatment and no need of changes to corticosteroids dose for the management of neurologic symptoms).
•11)Significant, uncontrolled, or active cardiovascular disease, specifically including
•12)Major surgery within 30 days of the first dose of brigatinib. Minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.
•13)Another primary malignancy other than NSCLC, except for adequately treated nonmelanoma skin cancer or cervical cancer in situ; definitively treated nonmetastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
•14)Symptomatic brain metastasis (parenchymal or leptomeningeal). Patients with asymptomatic brain metastasis or who have stable symptoms that did not require an increased dose of corticosteroids to control symptoms in the past 7 days before the first dose of brigatinib may be enrolled.
•15)Current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression are allowed
•16)Inability to swallow food or any co

研究者

发起方

FONDAZIONE RICERCA TRASLAZIONALE (FORT)

相似试验

进行中（未招募）

1 期

EUCTR2016-004989-25-ESIncyte Biosciences International Sàrl145

进行中（未招募）

1 期

A Phase 1/2 Study of Azacitidine in Combination With Pembrolizumab and Epacadostat Advanced Solid Tumors including Lung and Colorectal Cancer

EUCTR2016-004289-25-ESIncyte Corporation160

进行中（未招募）

1 期

A Phase 1/2 Study of Azacitidine in Combination With Pembrolizumab and Epacadostat Advanced Solid Tumors including Lung and Colorectal Cancer

EUCTR2016-004289-25-GBIncyte Corporation160

进行中（未招募）

1 期

A study exploring the safety, tolerability, and efficacy of INCAGN01876 in combination with immune therapies in subjects with advanced or metastatic malignancies.

EUCTR2016-004989-25-BEIncyte Biosciences International Sàrl450

进行中（未招募）

1 期

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Nivolumab in Select Advanced Cancers

EUCTR2016-002423-29-GBincyte Corporation291